Evidence map›Paper›PMID 35891437›Full record

ArticleViruses2022

Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors than Isoflavone and Flavones.

Otávio Augusto Chaves, Natalia Fintelman-Rodrigues, Xuanting Wang, Carolina Q Sacramento, Jairo R Temerozo, André C Ferreira, Mayara Mattos, Filipe Pereira-Dutra, Patrícia T Bozza, Hugo Caire Castro-Faria-Neto and 3 more

Abstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Review
  3. Identification of Anti-Viral Compounds fromJournal of microbiology and biotechnology · 2026
    Article
  4. Article
  5. [Application ofZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  6. Article
  7. Article
  8. Nature's cryptographic codebreakerFrontiers in microbiology · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Frontiers in microbiology · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Otávio Augusto ChavesLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil.ORCID 0000-0001-6211-7659
Natalia Fintelman-RodriguesLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil.ORCID 0000-0002-2332-8338
Xuanting WangCenter for Genome Technology and Biomolecular Engineering, Columbia University, New York, NY 10027, USA.ORCID 0000-0002-4198-7388
Carolina Q SacramentoLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil.ORCID 0000-0003-3952-7099
Jairo R TemerozoLaboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil.ORCID 0000-0002-8092-2149
André C FerreiraLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil.
Mayara MattosLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil.
Filipe Pereira-DutraLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil.ORCID 0000-0003-1917-2876
Patrícia T BozzaLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil.ORCID 0000-0001-8349-9529
Hugo Caire Castro-Faria-NetoLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil.
James J RussoCenter for Genome Technology and Biomolecular Engineering, Columbia University, New York, NY 10027, USA.
Jingyue JuCenter for Genome Technology and Biomolecular Engineering, Columbia University, New York, NY 10027, USA.ORCID 0000-0002-4974-4241
Thiago Moreno L SouzaLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil.

Funding

Virology CoreU19AI171401 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI David S Perlin, Charles M Rice · 2022 to 2026
$92.9M
NIAID NIH HHS U19 AI171401
6 · The paper itself

Abstract

Despite the fast development of vaccines, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still circulating and generating variants of concern (VoC) that escape the humoral immune response. In this context, the search for anti-SARS-CoV-2 compounds is still essential. A class of natural polyphenols known as flavonoids, frequently available in fruits and vegetables, is widely explored in the treatment of different diseases and used as a scaffold for the design of novel drugs. Therefore, herein we evaluate seven flavonoids divided into three subclasses, isoflavone (genistein), flavone (apigenin and luteolin) and flavonol (fisetin, kaempferol, myricetin, and quercetin), for COVID-19 treatment using cell-based assays and in silico calculations validated with experimental enzymatic data. The flavonols were better SARS-CoV-2 inhibitors than isoflavone and flavones. The increasing number of hydroxyl groups in ring B of the flavonols kaempferol, quercetin, and myricetin decreased the 50% effective concentration (EC

Indexed as

COVID-19 Drug TreatmentFlavonesIsoflavonesFlavonoidsFlavonolsHumansKaempferolsMolecular Docking SimulationProtease InhibitorsQuercetinSARS-CoV-2FlavonesFlavonoidsFlavonolsIsoflavonesKaempferolsProtease InhibitorsQuercetincalu-3 cellsCOVID-19exonucleaseflavonoidsmolecular dockingnatural productproteaseSARS-CoV-2

Identifiers

PMID35891437
PMCPMC9324382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.